*Plasmodium knowlesi*, a zoonotic parasite of long-tailed and pig-tailed macaques, is an important cause of human malaria in Southeast Asia \[[@CIT0001]\]. In some areas in this region, incidence has increased alongside the near-elimination of falciparum and vivax malaria, with *P. knowlesi* now the most common cause of malaria in Malaysia \[[@CIT0004]\] and parts of western Indonesia \[[@CIT0005]\].

Risk of severe disease from *P. knowlesi* is at least as high as from *Plasmodium falciparum* in coendemic areas \[[@CIT0008], [@CIT0009]\], occurring in 6%--9% of symptomatic adults \[[@CIT0010], [@CIT0011]\], and fatal cases have been reported \[[@CIT0004], [@CIT0009], [@CIT0011]\]. Independent risk factors for severe malaria include older age and increasing parasitemia \[[@CIT0010], [@CIT0017]\]; however, risk factors for death are poorly defined.

To delineate factors associated with knowlesi malaria mortality, we reviewed malaria deaths in Sabah, Malaysia, from 2015 to 2017, and conducted a systematic review of all previously reported fatal cases. *Plasmodium knowlesi* case fatality rates (CFRs) in Sabah during 2010--2017 were calculated using previously reported mortality and incidence data \[[@CIT0004], [@CIT0018]\].

METHODS {#s1}
=======

Case Series: Malaria Deaths, Sabah, 2015--2017 {#s2}
----------------------------------------------

All malaria deaths in Sabah from 2015--2017 were identified from the Sabah Department of Health. In Sabah, hospital admission and notification to the Department of Health are mandatory for all malaria cases, as is reporting of deaths. Since 2015 it has also been mandatory for a blood sample from all malaria cases to be sent to the state public health laboratory for *Plasmodium* species confirmation by polymerase chain reaction (PCR).

Case notes were retrieved from relevant health facilities and reviewed. Approval was obtained from the ethics committees of the Ministry of Health, Malaysia, and the Menzies School of Health Research, Australia.

Systematic Review of the Literature {#s3}
-----------------------------------

We searched Medline, PubMed, and Science Direct for articles published up to August 2018, containing the words "knowlesi AND death," "knowlesi AND fatality," or "knowlesi AND outcome," including synonyms and Medical Subject Heading terms. Relevant references cited within these articles were also reviewed.

Case Fatality Rates {#s4}
-------------------

*Plasmodium* *knowlesi* CFRs in Sabah were calculated from 2010 to 2017 using malaria incidence and fatality data from the Sabah Department of Health \[[@CIT0004], [@CIT0018]\]. Male and female CFRs were compared using Fisher exact test. Logistic regression was used to evaluate age and sex as independent risk factors for death.

RESULTS {#s5}
=======

Case Series: Malaria Deaths, Sabah, 2015--2017 {#s6}
----------------------------------------------

Six malaria deaths were reported to the Sabah Department of Health during 2015--2017, all confirmed by PCR as *P. knowlesi* monoinfections. Baseline demographic and clinical details are shown in [Tables 1](#T1){ref-type="table"} and [2](#T1){ref-type="table"}, laboratory details in [Table 3](#T3){ref-type="table"}, and severity criteria in [Table 4](#T4){ref-type="table"} (cases G1--G6). The median age was 40 (range, 23--58) years. Four (67%) cases were male; 3 (50%) were non-Malaysian citizens. Three (50%) cases had significant cardiovascular-metabolic comorbidities (severe mitral stenosis, ischemic heart disease, and morbid obesity with heart failure, respectively), and one other was pregnant. Median fever duration was 8 (range, 4--14) days. Five had severe malaria on presentation; intravenous (IV) artesunate was administered upon hospitalization in only 2 cases, with artesunate unavailable in 2 cases. Initial hospital microscopy correctly reported *P. knowlesi* in 2 (33%) cases; the others were reported as *Plasmodium malariae* (n = 2) and *P. falciparum* (n = 2). Median time from admission to death was 29 (range, 7--144) hours.

###### 

Article Summary, Demographics, and Treatment

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                              Year Published (Period)   Location   Case    Sex             Age, y   Fever, d   Malaysian Citizen   Correct Diagnosis^a^   Severe Diagnosis^b^   Initial Therapy IV   Therapy^c^      Time to Death, h
  ----------------------------------- ------------------------- ---------- ------- --------------- -------- ---------- ------------------- ---------------------- --------------------- -------------------- --------------- ------------------
  Cox-Singh et al \[[@CIT0014]\]      2008\                     Sarawak    A1      F               66       3          NR                  N                      N                     N                    CQ, SP          35
                                      (2001--2006)                                                                                                                                                                           

                                                                           A2      M               69       3          NR                  Y                      Y                     NR                   Q               141

                                                                           A3      M               39       3          NR                  Y                      Y                     N                    CQ, SP          5

                                                                           A4      M               40       7          NR                  Y                      Y                     Y                    CQ, SP, PQ, Q   316

  Daneshvar et al \[[@CIT0011]\]\     2009\                     Sarawak    B1      F               68       NR         NR                  NR                     Y                     Y                    Q               6
                                      (2006--2008)                                                                                                                                                                           

                                                                           B2      F               36       NR         NR                  NR                     Y                     Y                    Q               24

  Cox-Singh et al \[[@CIT0016]\]      2010                      Sarawak    C1      M               40       5          Y                   N                      N                     N                    None            2

  William et al \[[@CIT0009]\]        2011\                     Sabah      D1      F               76       NR         Y                   NR                     Y                     Y                    Q               96
                                      (2007--2009)                                                                                                                                                                           

                                                                           D2      F               65       5          Y                   NR                     Y                     Y                    Q               96

                                                                           D3      M               57       7          Y                   NR                     Y                     Y                    Art             48

                                                                           D4      F               84       5          Y                   NR                     Y                     Y                    Q               96

                                                                           D5      M               56       5          Y                   NR                     Y                     Y                    Q               \<24

                                                                           D6      M               46       7          Y                   NR                     Y                     Y                    Q               24

  Rajahram et al \[[@CIT0012]\]       2013\                     Sabah      E1      M               71       7          NR                  Y                      N                     Y                    Q, PQ, CQ, D    1
                                      (2010--2011)                                                                                                                                                                           

                                                                           E2      M               65       2          NR                  N                      N                     N                    CQ              75

                                                                           E3      M               51       4          NR                  Y                      Y                     Y                    Art             16

                                                                           E4      M               50       7          NR                  Y                      Y                     N                    CQ              56

                                                                           E5      F               49       4          NR                  Y                      N                     N                    CQ, PQ          63

                                                                           E6^d^   F               36       7          NR                  Y                      N                     N                    SP, PQ          84

  Rajahram et al^e^ \[[@CIT0004]\]\   2016\                     Sabah      F1      M               31       7          Y                   N                      N                     Y                    Art, D          216
                                      (2012--2014)                                                                                                                                                                           

                                                                           F2^f^   F               71       5          Y                   Y                      Y                     Y                    Art, D          12

                                                                           F3      F               61       7          Y                   Y                      Y                     Y                    Art             7

                                                                           F4      M               56       3          N                   Y                      Y                     Y                    Art, D          41

                                                                           F5      F               57       7          N                   Y                      N                     Y                    Art, PQ, CQ     NR

                                                                           F6      M               73       7          Y                   Y                      NR                    Y                    Art, D          72

                                                                           F7      F               62       6          Y                   Y                      N                     N                    A-M             23

  Newly reported                      2018\                     Sabah      G1^g^   F               32       14         Y                   Y                      Y                     N                    A-L, D^h^       10.5
                                      (2015--2017)\                                                                                                                                                                          

                                                                           G2^i^   M               50       7          N                   Y                      Y                     Y                    Art             7

                                                                           G3      F               37       4          Y                   N                      N                     N                    None            43

                                                                           G4      M               42       5          N                   Y                      N                     N                    A-L             15

                                                                           G5      M               32       9          Y                   Y                      Y                     Y                    Art             144

                                                                           G6      M               58       9          N                   Y                      Y                     Y^h^                 Art^h^          70

  Total (%)                                                                ...     M: 18/32 (56)   56^j^    6^j^       15/20 (75)          ...                    19/24 (79)            20/31 (65)           ...             41^j^
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: A-L, artemether-lumefantrine; A-M, artemether-mefloquine; Art, artesunate; CQ, chloroquine; D, doxycycline; F, female; IV, intravenous; M, male; N, no; NR, not reported; PQ, primaquine; Q, quinine; SP, sulfadoxine-pyrimethamine; Y, yes.

^a^Diagnosed as malaria at presentation.

^b^Diagnosed as severe malaria at presentation.

^c^Initial therapy on malaria diagnosis.

^d^ *Plasmodium knowlesi--*associated, gram-negative sepsis.

^e^One fatal case of microscopy-diagnosed "*Plasmodium malariae*" was described in this series, but has not been included in the review due to lack of polymerase chain reaction confirmation.

^f^This patient was also described in a separate case report \[[@CIT0013]\].

^g^Thirty-five weeks' gestation at presentation.

^h^IV therapy not available at presenting hospital.

^i^This patient was previously reported in a prospective observational study \[[@CIT0010]\].

^j^Values are presented as the median.

###### 

Laboratory Features on Presentation

  Case     Hb, g/dL   WBC, × 10^3^ Cells/µL   Plt, × 10^9^ Cells/µL   Na, mmol/L   Creat, µmol/L   Urea, µmol/L   Bili, µmol/L   AST, U/L   ALT, U/L   Alb, g/L   HCO~3~, mmol/L   Lac, mmol/L   Species^a^   Parasites/µL Blood
  -------- ---------- ----------------------- ----------------------- ------------ --------------- -------------- -------------- ---------- ---------- ---------- ---------------- ------------- ------------ --------------------
  A1       10.6       16.7                    22                      NR           500             61             79             122        104        24         NR               NR            Pm           204 800
  A2       15.2       6.6                     25                      NR           NR              26             300            163        77         15         NR               NR            Pm           75 000
  A3       15.4       13.4                    24                      NR           NR              19             NR             NR         NR         NR         NR               NR            Pm           112 000
  A4       11.9       11.4                    24                      NR           557             25             490            87         82         28         NR               NR            Pm           ++++
  B1       NR         NR                      NR                      NR           320             NR             NR             NR         NR         NR         NR               17.4          NR           222 570
  B2       NR         NR                      NR                      NR           NR              NR             178            NR         NR         NR         NR               NR            NR           214 000
  C1       12.7       10.1                    43                      126          NR              34             NR             131        NR         NR         NR               NR            NR           NR
  D1       14.6       6.1                     42                      129          173             29             660            110        145        28         20               NR            Pm           4+
  D2       12.6       20.1                    26                      128          492             50             103            67         85         32         17               NR            Pm           4+
  D3       9.4        20                      35                      133          819             73             397            19         230        24         10.7             NR            Pm           4+
  D4       10.5       9.7                     34                      129          239             NR             NR             NR         NR         NR         NR               NR            Pm           2+
  D5       15.4       11.9                    28                      128          380             NR             NR             NR         NR         NR         11               NR            Pm           4+
  D6       16.8       21.6                    16                      134          526             23             640            210        275        26         12               NR            Pm           4+
  E1       14.9       10.8                    88                      NR           1451            82             NR             42         NR         NR         NR               NR            Pf           3+
  E2       14.6       4.8                     58                      NR           NR              6              NR             NR         NR         NR         NR               NR            Pm           3+
  E3       9.4        6.8                     8                       NR           578             44             146            53         28         23         14               6.4           Pm           4+
  E4       10.9       7.81                    3                       NR           330             39             74             NR         49         19         16.2             6.8           Pv           4+
  E5       12.6       12.1                    32                      NR           283             25             25             39         20         28         14               NR            Pm           4+
  E6       11.1       7.8                     53                      NR           NR              11             NR             NR         NR         NR         6.5              NR            Pm           1+
  F1       12.9       6.9                     25                      NR           915             38             254            67         NR         28         11.5             3.6           Pf           92 500
  F2       14.1       13.3                    53                      NR           662             36             108            322        145        24         4.2              NR            Pm           71 939
  F3       12.6       20.5                    8                       NR           453             34             315            732        258        20         10.3             NR            Pm           320 000
  F4       13.8       12.1                    73                      NR           171             12             43             373        143        24         11.6             NR            Pk           6471
  F5       11.1       5.3                     26                      NR           143             12             46             NR         NR         27         14.3             NR            Pv           9866
  F6       11         8.2                     67                      NR           132             14             234            61         36         20         16               NR            Pm           4+
  F7       12         11.2                    60                      NR           124             6              NR             NR         NR         NR         NR               NR            Pm           22 666
  G1       15.8       19.5                    49                      123          131             11             NR             NR         NR         NR         NR               NR            Pk           22 400
  G2       9.9        8.5                     63                      121          609             50             NR             NR         NR         NR         NR               NR            Pk           71 939
  G3       13.2       12                      159                     118          326             15             32             37         24         31         12.7             NR            Pf           3+
  G4       13.1       7.6                     44                      123          481             33             36             122        57         18         12.8             NR            Pm           1+
  G5       14.3       6.4                     76                      128          120             9              38             21         14         NR         22.3             NR            Pm           4+
  G6       8.3        18                      104                     128          230             27             84             54         31         26         15               1.96          Pf           ++++
  Median   12.7       11                      38.5                    128          355             26.5           108            77         79.5       24         12.8             6.4           ...          ...

Blood culture results were available in 14 cases: 13 were negative at 3 days of incubation, and 1 (E6) grew *Enterobacter cloacae*. ++++ indicates \>4,000 parasites/µL.

Abbreviations: Alb, albumin; ALT, serum alanine aminotransferase; AST, serum aspartate aminotransferase; Bili, serum bilirubin; creat, serum creatinine, Hb, plasma hemoglobin; HCO~3~, serum bicarbonate; Lac, serum lactate; Na, serum sodium; NR, not reported; Pf, *Plasmodium falciparum*; Pm, *Plasmodium malariae*; Pk, *Plasmodium knowlesi*; Plt, platelet count; Pv, *Plasmodium vivax*; Urea, serum urea; WBC, white blood cell count.

^a^ *Plasmodium* species by microscopy.

###### 

Severity Criteria on Presentation

  Case                 Anemia     AKI          Hypoglycemia   Acidosis     Hyperparasitemia   Jaundice     Coma^a^    Shock        Bleeding   Respiratory Distress   Total
  -------------------- ---------- ------------ -------------- ------------ ------------------ ------------ ---------- ------------ ---------- ---------------------- -------
  A1                   N          Y            NR             NR           Y                  Y            N          N            N          N                      3
  A2                   N          NR           NR             NR           N                  Y            N          N            N          Y                      2
  A3                   N          NR           NR             NR           Y                  Y            N          N            N          N                      2
  A4                   N          Y            NR             NR           Y                  Y            N          N            N          N                      3
  B1                   N          Y            Y              Y            Y                  Y            NR         Y            NR         Y                      7
  B2                   N          N            N              N            Y                  Y            NR         N            NR         Y                      3
  C1                   N          NR           NR             NR           Y                  NR           N          Y            N          Y                      3
  D1                   N          Y            Y              Y            NR                 Y            N          Y            N          Y                      6
  D2                   N          Y            N              Y            NR                 Y            N          Y            N          Y                      5
  D3                   N          Y            Y              Y            NR                 Y            N          Y            N          Y                      6
  D4                   N          Y            N              N            NR                 N            N          N            N          Y                      2
  D5                   N          N            N              N            NR                 N            N          Y            N          Y                      2
  D6                   N          Y            N              N            NR                 Y            N          N            N          Y                      3
  E1                   N          Y            NR             NR           NR                 NR           N          Y            NR         Y                      3
  E2                   N          NR           NR             NR           NR                 NR           N          N            N          N                      0
  E3                   N          Y            NR             Y            NR                 Y            N          Y            N          Y                      5
  E4                   N          Y            NR             Y            NR                 Y            N          N            N          Y                      4
  E5                   N          Y            NR             Y            NR                 N            N          N            N          Y                      3
  E6                   N          NR           NR             Y            N                  NR           N          N            N          N                      1
  F1                   N          Y            NR             Y            N                  Y            N          N            N          N                      3
  F2                   N          Y            Y              Y            Y                  Y            N          N            N          N                      5
  F3                   N          Y            NR             Y            Y                  Y            N          N            N          Y                      5
  F4                   N          N            NR             Y            N                  N            Y^b^       N            N          Y                      3
  F5                   N          N            NR             NR           N                  Y            N          N            N          N                      1
  F6                   N          N            NR             N            NR                 Y            N          Y            N          N                      2
  F7                   N          N            NR             NR           Y                  NR           N          N            N          N                      1
  G1                   N          N            NR             NR           N                  NR           N          Y            N          Y                      3
  G2                   N          Y            NR             NR           Y                  NR           N          N            N          N                      2
  G3                   N          Y            NR             Y            NR                 N            N          N            N          N                      2
  G4                   N          Y            NR             Y            NR                 N            N          Y            N          Y                      4
  G5                   N          N            Hyper          N            N                  N            N          N            N          N                      0
  G6                   N          Y            Hyper          Y            Y                  Y            N          Y            N          Y                      6
  Frequency, No. (%)   0/32 (0)   19/27 (70)   4/11 (36)      15/21 (71)   11/18 (61)         18/25 (72)   1/30 (3)   12/32 (38)   0 (0)      19/32 (59)             

Definitions of severe *Plasmodium knowlesi* malaria criteria: severe anemia, hemoglobin \<7.0 g/dL (adults) or \<5.0 g/dL (children); AKI, creatinine \>265 µmol/L; hypoglycemia, blood glucose \<2.2 mmol/L; metabolic acidosis, bicarbonate \<15 mmol/L or lactate \>5 mmol/L; hyperparasitemia, parasite count \>100 000 parasites/µL (or \>2% infected red blood cells); jaundice, bilirubin \>50 µmol/L, with parasitemia \>20 000/µL and/or creatinine \>132 µmol/L; coma, Glasgow Coma Scale (GCS) \<11; shock, systolic blood pressure \<80 mm Hg with cool peripheries or impaired capillary refill; significant abnormal bleeding; respiratory distress, oxygen saturation \<92% with respiratory rate \>30 breaths/minute.

Abbreviations: AKI, acute kidney injury; Hyper, hyperglycemia; N, no; NR, not reported; Y, yes.

^a^Not reported to date in knowlesi malaria.

^b^Alternative causes for reduced GCS not excluded.

### Case 1 (G1) {#s7}

A 32-year-old pregnant woman at 35 weeks' gestation (G6P5) presented with reduced fetal movement, 14 days of fever, and 2 days of intermittent abdominal pain and dyspnea. She was hypotensive, tachycardic, hypoxic, and tachypneic. She had hyponatremia, thrombocytopenia, and acute kidney injury (AKI). She was intubated, ventilated, and given IV ceftriaxone, sodium bicarbonate, and ionotropic support. A chest radiograph showed diffuse interstitial infiltrates consistent with acute respiratory distress syndrome (ARDS). A blood film taken 4 hours after admission was reported as *P. knowlesi*, with 22 400 parasites/µL. Oral artemether-lumefantrine and doxycycline were given, and tertiary hospital transfer was arranged for IV artesunate; however, the patient had a cardiac arrest while awaiting transfer. Admission blood cultures were negative.

### Case 2 (G2) {#s8}

A 50-year-old male Indonesian palm-oil plantation worker presented to a district hospital with 1 week of fever, rigors, headache, epigastric pain, and diarrhea. Physical examination revealed hepatomegaly (3 cm), but was otherwise unremarkable. He had severe AKI, hyponatremia, and thrombocytopenia. A blood film was reported as *P. knowlesi* with 71 939 parasites/µL. Chest radiography showed generalized interstitial infiltrates. He was diagnosed with severe malaria and commenced on IV artesunate, and a tertiary hospital transfer was arranged; however, he arrested en route. This case has been previously documented \[[@CIT0010]\].

### Case 3 (G3) {#s9}

A 37-year-old woman with a history of gestational hypertension presented to a district hospital with 4 days of fever, rigors, epigastric pain, dizziness, and vomiting. She was hypotensive, tachycardic, and had epigastric tenderness. The initial diagnosis was dyspepsia, and she received ranitidine, prochlorperazine, and fluid resuscitation. AKI was noted 2 hours after admission, and IV ceftriaxone was initiated for presumed sepsis. Twelve hours after hospitalization, she became tachypneic, with reduced consciousness (Glasgow Coma Scale reported as 9/15), and severe metabolic acidosis (arterial pH, 7.02; bicarbonate, 2.5 mEq/L). She underwent intubation, ventilation, and hemodialysis and received IV sodium bicarbonate and imipenem. The patient deteriorated further on day 2, with transaminitis (alanine aminotransferase \[ALT\] level, 426 U/L; aspartate aminotransferase \[AST\] level, 1481 U/L), metabolic acidosis, and coagulopathy (international normalized ratio \[INR\], 1.9; prothrombin time, 52 seconds) requiring fresh frozen plasma. The patient arrested 43 hours after admission. Blood films taken prior to death were reported as *P. malariae* with 2285 parasites/µL. It was later noted that an admission blood film had been reported as "*P. falciparum* 3+." No antimalarial treatment had been given. Blood cultures were negative.

### Case 4 (G4) {#s10}

A 32-year-old Filipino man presented with 5 days of fever, cough, and coryzal symptoms. He was tachycardic, but physical examination was otherwise unremarkable. He was given fluids and acetaminophen (paracetamol). A blood smear was reported as "*P. malariae* 1+" with AKI, hyponatremia, and thrombocytopenia also noted. Oral artemether-lumefantrine was given. Twenty-two hours after admission, the patient had hemoptysis with tachypnea and hypoxia. A chest radiograph showed generalized interstitial infiltrates. A diagnosis of severe *P. malariae* with ARDS was made and IV artesunate was initiated. After further hemoptysis, a bedside ultrasound showed pleural and pericardial effusions and noninvasive ventilation was initiated. At 48 hours, massive hemoptysis occurred. He required intensive care unit admission, intubation, ventilation, inotropic support, hemodialysis for metabolic acidosis and uremia, and red cell and fresh frozen plasma transfusions. Echocardiography (ECG) showed severe mitral stenosis. Admission blood cultures were negative. He died on day 4, with cause of death recorded as severe malaria with pulmonary hemorrhage and underlying mitral stenosis.

### Case 5 (G5) {#s11}

A 42-year-old fisherman with morbid obesity, obstructive sleep apnea, and congestive cardiac failure was referred to a district hospital from a peripheral clinic with 9 days of fever, and 3 days of dyspnea, epigastric pain, and vomiting. The clinic blood film was reported as "complicated malaria with hyperparasitemia"; *Plasmodium* species was not specified. On admission he was tachycardic, hypotensive, and hypoxic. ECG showed atrial fibrillation at 160 beats per minute. He received IV artesunate, fluid resuscitation, and high-flow oxygen. He was hyponatremic, with AKI, hyperglycemia, and a compensated metabolic acidosis. A blood film was reported as "*P. malariae* 4+." He required intubation, hemodialysis, IV insulin, digoxin, and inotropic support. Seven hours postadmission, ECG showed cardiac ischemia, and at 15 hours the patient arrested. Admission blood cultures were negative. Cause of death was recorded as (1) malaria with hyperparasitemia, and (2) decompensated cardiac failure, with likely underlying cardiomyopathy.

### Case 6 (G6) {#s12}

A 58-year-old Caucasian expatriate man with a history of ischemic heart disease, left bundle-branch block, hypertension, and paroxysmal atrial fibrillation presented to a private hospital with 9 days of fever, palpitations, and lethargy. He was hypotensive, hypoxic, and tachypneic. A blood smear was reported as "heavy infection, likely *P. falciparum*." He was anemic, hyperbilirubinemic, and hyponatremic, with AKI and metabolic acidosis. He was commenced on ionotropic support and transferred to a tertiary public hospital for IV artesunate. There he also received ceftriaxone; hydrocortisone; insulin infusion for hyperglycemia; cardioversion for ventricular tachycardia; and, later, intubation, ventilation, and continuous venovenous hemofiltration. A blood film on day 1 was reported as *P. knowlesi* with 246 100 parasites/µL. On day 2, he had worsening metabolic acidosis (lactate, 11.7 mmol/L; pH, 7.13; bicarbonate, 10.4 mEq/L), coagulopathy (INR, 4.53), and transaminitis (AST, \>4200 U/L; ALT, 1820 U/L), with a bilirubin of 247 μmol/L, and was anuric. He died on day 3, with cause of death recorded as severe knowlesi malaria with multiorgan failure.

Systematic Review of *P. knowlesi* Fatalities {#s13}
---------------------------------------------

Ten original research articles reporting *P. knowlesi* fatalities were identified ([Figure 1](#F1){ref-type="fig"}). Thirty PCR-confirmed *P. knowlesi* deaths were reported: 19 from Sabah and 11 from Sarawak, Malaysia, all occurring during 2001--2014. Four of the Sarawak deaths were excluded from further review due to insufficient individual patient data \[[@CIT0015]\].

![Flow diagram of systematic review. ^a^Four retrospective case series or studies \[[@CIT0004], [@CIT0009], [@CIT0012], [@CIT0014]\], 2 prospective observational studies \[[@CIT0010], [@CIT0011]\], 1 case-control study \[[@CIT0015]\], 2 case reports \[[@CIT0013], [@CIT0016]\], and 1 review of autopsies \[[@CIT0035]\]. ^b^Four reported deaths were excluded from further review as sufficient individual patient data were not available \[[@CIT0015]\]. ^c^Nineteen deaths occurred in Sabah and 7 in Sarawak, Malaysia, all during 2001--2014.](ciz011f0001){#F1}

Demographic, clinical, and laboratory details for each case are summarized in [Tables 1--3](#T1){ref-type="table"}, with severity criteria shown in [Table 4](#T4){ref-type="table"}. Combining these 26 previously reported cases with the 2015--2017 series, median age was 56 (range, 23--84) years, and 18 (56%) were male. Female fatal cases were older than male fatal cases (median age, 62 vs 51 years, respectively), although this was not statistically significant. Median duration of fever was 6 (interquartile range, 4--7) days, with no difference between women and men. At presentation, 30 of 32 (94%) patients met the World Health Organization (WHO) criteria for severe malaria, although only 19 of these 30 (63%) were recognized as having severe malaria. Of those meeting severity criteria, the median number of criteria was 3 (range, 1--7), with the most frequent criteria being respiratory distress (n = 19/32 \[59%\]), jaundice (n = 18/25 \[72%\]), and severe AKI (n = 19/27 \[70%\]). Abdominal pain was reported in 17 of 26 (65%) cases. Decreased conscious state was reported on presentation in 1 case; however, alternative causes were not excluded \[[@CIT0004]\]. Cardiovascular-metabolic comorbidities were a notable factor of previously reported cases as well as in the current series. Overall, hypertension was reported in 8 of 32 (25%) cases and stress hyperglycemia or diabetes mellitus in 12%.

###### 

Clinical Features on Presentation

  --------------------------------------------------------------------------------------------------------------------------
  Case     BP,\     HR, Beats/Min   O~2~, %   RR,\          Temperature, °C   Abdominal Pain^a^   Comorbidities\
           mm Hg                              Breaths/Min                                         or Pregnancy
  -------- -------- --------------- --------- ------------- ----------------- ------------------- --------------------------
  A1       120/90   88              NR        NR            36.8              Y                   ...

  A2       124/66   132             NR        NR            38.0              Y                   ...

  A3       81/51    84              NR        NR            36.0              Y                   ...

  A4       132/67   84              NR        NR            36.0              Y                   ...

  B1       80 sys   NR              NR        NR            NR                NR                  ...

  B2       NR       NR              NR        NR            NR                NR                  HTN

  C1       U        NR              NR        NR            NR                Y                   ...

  D1       126/70   130             85        NR            36.8              NR                  IHD

  D2       136/57   101             56        NR            38.0              N                   NR

  D3       100/50   110             90        NR            36.7              Y                   NR

  D4       120/69   94              NR        NR            38.5              N                   NR

  D5       90/50    130             89        NR            37.5              NR                  NR

  D6       80/50    120             90        NR            37.9              Y                   NR

  E1       75/49    127             75        NR            39.4              NR                  HTN, COPD

  E2       117/73   58              92        NR            36.8              N                   HTN, T2D

  E3       70/40    110             90        NR            37.6              Y                   ...

  E4       83/51    89              60        NR            37.5              N                   ...

  E5       112/51   113             88        NR            36.7              NR                  ...

  E6       131/87   110             85        NR            37.8              Y                   ...

  F1       129/72   108             97        24            37.4              Y                   ...

  F2       127/87   108             96        38            37.0              Y                   HTN

  F3       112/79   124             88        26            36.8              Y                   HTN

  F4       85/60    150             81        25            36.2              N                   ...

  F5       193/96   129             98        22            39.0              N                   HTN, T2D

  F6       80/49    72              100       20            37.7              N                   TB

  F7       116/71   111             96        22            39.9              N                   HTN

  G1       69/50    138             71        46            37.0              Y                   Pregnancy

  G2       106/64   80              96        18            36.8              Y                   ...

  G3       96/36    104             100       16            36.6              Y                   ...

  G4       U        126             98^b^     20            36.3              N                   Severe MR, TR

  G5       105/64   129             98        26            37.6              Y                   Morbid obesity, CCF, OSA

  G6       78/45    86              88        27            39.7              Y                   IHD, HTN, PAF

  Median   ...      110             90        24            37.4              ...                 ...
  --------------------------------------------------------------------------------------------------------------------------

Abbreviations: BP, blood pressure; CCF, congestive cardiac failure; COPD, chronic obstructive pulmonary disease; HR, heart rate; HTN, hypertension; IHD, ischemic heart disease; MR, mitral valve regurgitation; N, no; NR, not reported; O~2~, oxygen saturation; OSA, obstructive sleep apnea; PAF, paroxysmal atrial fibrillation; RR, respiratory rate; Sys, systolic; T2D, type 2 diabetes mellitus; TB, tuberculosis; TR, tricuspid valve regurgitation; U, unrecordable; Y, yes.

^a^Previously demonstrated as a risk factor for severe malaria.

^b^Fifteen liters/minute high-flow oxygen.

Among all fatal cases, species diagnosis on admission microscopy was incorrect in 26 of 29 (90%), including 20 (69%) diagnosed as *P. malariae*, 4 (14%) as *P. falciparum*, and 2 (7%) as *Plasmodium vivax*. Thrombocytopenia was universal on presentation, as was elevated creatinine ([Table 3](#T3){ref-type="table"}). All patients with an available serum sodium result were hyponatremic. No patient had severe anemia at presentation. Intravenous antimalarial treatment was administered on presentation in 17 of 21 (81%) cases with severe malaria on presentation. Median time to death was 41 (range, 1--316) hours.

Case Fatality Rates {#s14}
-------------------

The *P. knowlesi* CFR in Sabah was 1.70/1000 (95% confidence interval \[CI\], 1.66--1.75; 6/3524) during 2015--2017. For women this was 3.6/1000 (95% CI, 3.4--3.8; 2/558), compared to 1.4/1000 (95% CI 1.3--1.4; 4/2966) for men (*P* = .24). Incorporating previously reported data from 2010 to 2014 (6 deaths among 783 *P. knowlesi* cases in women; 7 deaths among 3443 cases in men) \[[@CIT0004]\], the overall CFR during 2010--2017 was 2.45/1000 cases (95% CI, 2.42--2.49; 19/7750): 6.0/1000 (95% CI 5.9--6.1; 8/1341) for women and 1.7/1000 (95% CI, 1.7--1.8; 11/6409) for men (*P* = .01). The higher CFR in women remained significant after adjusting for age (odds ratio \[OR\], 2.6 \[95% CI, 1.0--6.7\]; *P* = .043). The CFR for patients aged ≥45 years was 5.8/1000 (95% CI, 5.7--5.9; 13/2228) compared to 1.1/1000 (95% CI, 1.0--1.1; 6/5514) for those aged \<45 years (*P* \< .001). Age ≥45 years remained a significant risk factor for death after adjusting for sex (OR, 4.7 \[95% CI, 1.8--12.5\]; *P* = .002).

DISCUSSION {#s15}
==========

We describe 6 malaria deaths in Sabah during 2015--2017, and review 26 previously reported *P. knowlesi* deaths. *Plasmodium knowlesi* accounted for all recent malaria deaths in Sabah, in contrast to previous reports during 2010--2014 where 13 of 29 (44%) deaths were attributed to *P. knowlesi* \[[@CIT0004], [@CIT0012]\]. This increase in proportion of fatal cases attributed to *P. knowlesi* is consistent with the decline of falciparum and vivax malaria in Sabah, and the ongoing increase in cases of *P. knowlesi* \[[@CIT0004], [@CIT0018]\]. The fact that the total number of *P. knowlesi* deaths per year has remained relatively stable despite this increasing incidence is consistent with previously reported declining CFRs in Sabah \[[@CIT0004]\], likely reflecting ongoing increases in awareness and improved management of severe knowlesi malaria.

It is notable that all reported fatal cases were adults. This is consistent with the absence of severe knowlesi malaria in children \[[@CIT0010], [@CIT0019]\], and is in marked contrast to the predominance of severe and fatal malaria from *P. falciparum* and *P. vivax* in the pediatric age group \[[@CIT0020]\]. Older age is a known risk factor for severe knowlesi malaria \[[@CIT0008], [@CIT0010], [@CIT0017]\], and in this study age ≥45 years was associated with a 5-fold increase in risk of death. It was also notable that nearly half of all reported fatal cases were women. This contrasts with the predominance of men in studies of nonfatal knowlesi malaria, with men consistently accounting for 75%--80% of cases \[[@CIT0021], [@CIT0022]\]. We previously hypothesized that the higher CFR in women with knowlesi malaria was due in part to their older median age \[[@CIT0004]\]. However, here we now demonstrate that women are more than twice as likely to die from knowlesi malaria even after adjusting for age. There was no difference in parasitemias between male and female fatal cases, nor any difference in fever duration, suggesting that the higher mortality was not due to delays in health-seeking behavior. A higher risk of death in females has also been noted in other severe infections \[[@CIT0023]\]. Further studies are required to investigate the pathogenic or other factors that may account for this increased risk \[[@CIT0024]\].

Respiratory distress and AKI were the most common severity criteria on presentation in fatal cases. Abdominal pain, previously reported as a risk factor for severe knowlesi malaria \[[@CIT0010]\], was present in 53% of all cases. Potential explanations include gut ischemia from microvascular accumulation of parasitized red cells and/or gastric ulceration \[[@CIT0014]\]. Thrombocytopenia was universal among fatal cases. This may relate to the higher proportion of platelet binding to infected red cells found in *P. knowlesi* compared with other species \[[@CIT0026]\]. Hyponatremia, a known metabolic abnormality in severe falciparum and knowlesi malaria \[[@CIT0008], [@CIT0010], [@CIT0027]\], was present in all fatal cases. Hypoglycemia occurred in 15% of previously reported fatal cases; however, in this series, 2 cases of hyperglycemia associated with death also occurred. This may relate to the older age of knowlesi-infected patients with severe malaria \[[@CIT0008], [@CIT0017]\], and rising prevalence of metabolic syndrome with age.

Comorbidities are a notable feature in fatal knowlesi malaria. Half of the newly described cases had underlying cardiovascular-metabolic disease (including severe mitral stenosis, heart failure, and morbid obesity), and hypertension and hyperglycemia or diabetes mellitus were also common in the previously reported cases. Cardiovascular disease and metabolic syndrome are known to be associated with increased systemic inflammation, endothelial activation, and microvascular dysfunction \[[@CIT0028]\], all features of severe knowlesi malaria \[[@CIT0017]\]. It is thus plausible that cardiovascular-metabolic disease would increase the risk of severe knowlesi malaria, as has been reported in falciparum malaria \[[@CIT0029]\].

This series includes the first report of fatal knowlesi malaria in pregnancy, occurring at 35 weeks' gestation. *Plasmodium knowlesi* is relatively rare in pregnancy, with only 5 cases reported previously \[[@CIT0009], [@CIT0030]\]. Pregnancy is known to increase risk of severe maternal disease in falciparum malaria \[[@CIT0020]\]. Of the 5 previously described cases of *P. knowlesi* in pregnancy, 1 had severe malaria with intrauterine death, 2 had moderate anemia, and 1 delivered a preterm low-birth-weight infant \[[@CIT0009], [@CIT0030]\]. With the current fatal case, 2 of 6 (33%) reported cases of *P. knowlesi* in pregnancy have resulted in severe maternal malaria and fetal death. Prospective studies are required to further evaluate the true risks and consequences of knowlesi malaria in pregnancy.

Several health-system issues contributed to deaths in this newly reported series. In 3 cases, the diagnosis of severe malaria was delayed despite the presence of compatible clinical features, and in another 2, IV artesunate was not available. Half of the cases were non-Malaysian citizens, which, together with the long duration of fever in this series (median, 8 days), suggests possible barriers to accessing healthcare. These findings highlight the need to evaluate strategies to improve healthcare access in endemic areas, in addition to ensuring availability of appropriate antimalarials at all facilities. In the combined analysis, 90% of fatal cases had an alternative *Plasmodium* species diagnosed on admission microscopy. This is consistent with the inability of routine microscopy to reliably distinguish *P. knowlesi* from other species \[[@CIT0031]\], which, combined with the poor sensitivity and specificity of available rapid diagnostic tests \[[@CIT0032], [@CIT0033]\], highlights the importance of a unified treatment strategy of IV artesunate for severe malaria from any species \[[@CIT0020], [@CIT0034]\].

A limitation of this study was the retrospective nature of the case series, resulting in either incomplete or unvalidated data. In particular, parasite counts were surprisingly low in some cases (G4 and G3), and it is possible that blood films may have been misreported. Second, the Department of Health data used to calculate CFRs did not include parasite counts, and hence the contribution of parasitemia to age and sex as risk factors for death could not be evaluated. *Plasmodium knowlesi* parasitemia is known to increase with age; however, age has been shown to be an independent risk factor for severe knowlesi malaria \[[@CIT0010], [@CIT0017]\], and hence would be expected to be an independent risk factor for death. In the largest prospective studies conducted to date \[[@CIT0010], [@CIT0017]\], an independent association between parasitemia and sex was not found; thus, a difference in parasitemia is unlikely to account for the increased CFR in women. Finally, it is possible that not all cases of *P. knowlesi* are notified, so the CFRs reported in this manuscript may overestimate the true CFRs.

In conclusion, this review highlights the potential for poor outcomes from knowlesi malaria, and identifies female sex, age ≥45 years, and comorbidities as important associated factors. With the near-elimination of falciparum and vivax malaria in Sabah, Malaysia, health systems must maintain efforts to promptly diagnose and treat patients with knowlesi malaria to avoid fatal outcomes, particularly in these at-risk groups. This will require ongoing surveillance and efforts to increase awareness among communities and health providers, as well as improving access to healthcare and ensuring availability of appropriate antimalarials at all health facilities.
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